A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

Eye

Volumn 24, Issue 10, 2010, Pages 1561-1567

  Vallance, J H ^a   Johnson, B ^a   Majid, M A ^a   Banerjee, S ^a   Mandal, K ^a   Bailey, C C ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

clinical trials; degeneration; macula; Neovascularisation; treatment medical

Indexed keywords

CHLORAMPHENICOL; RANIBIZUMAB; VERTEPORFIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXPLORATORY RESEARCH; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MONOTHERAPY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PERFUSION; PHOTODYNAMIC THERAPY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 78049468685     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.84     Document Type: Article

References (12)

1. Mitchell P, Korobelnik J-F, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94(1):2-13. Published Online First: 20 May 2009, doi:10.1136/bjo.2009. 159160.
2. Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina 2009;29(6 Suppl): S5-S7.
3. Shah GV, Sang DN, Hughes MS. Verteporfin combination regimes in the treatment of neovascular age-related macular degeneration. Retina 2009;29:133-148.
4. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542.
5. Schmidt-Erfurth U, Wolf S, PROTECT Study Group. Same-Day administration of verteporfin and ranibizumab 0.5mg in patients with choroidal neovascularisation due to agerelated macular degeneration. Br J Ophthalmol 2008;92:1628-1635.
6. Kaiser PK, Registry of Visudyne AMD writing committe. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116(4):747-755.
7. Guidelines for Intravitreal Injections Procedure 2009. http://www.rcophth.ac.uk/about/publications/. (accessed on 21 May 2010).
8. Pruente C, Hatz K, Henrich PB, Braun B, Sacu S, Schneider U. A randomised double-masked study comparing lucentis monotherapy and pdt combined with lucentis therapy in patients with exudative amd: one year results for bcva and retreatment frequency. Presented at ARVO May 2009, abstract at http://arvo.abstractsonline.com/plan/SSResults.aspx. (accessed on 13 September 2009).
9. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003;110:1306-1314.
10. Piermarocchi S, Sartore M, Lo Giudice G, Maritan V, Midena E, Segato T. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy. Arch Ophthalmol 2008;126(10):1367-1374.
11. Kiss CG, Simader C, Michels S, Schmidt-Erfurth U. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the PROTECT study. Br J Ophthalmol 2008;92:1620-1627.
12. Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res 2009;28:145-154.